Here are four things to know:
1. Ms. Whitaker is the president and CEO of Synta Pharmaceuticals.
2. She has extensive experience in sales, marketing and commercial management of gastrointestinal and oncology products.
3. Before joining Synta, she was president of North American Pharmaceuticals for Sanofi, where she headed Sanofi’s collaboration with AgaMatrix.
4. Synta’s current COO and Vice president Chen Schor will take over as president and CEO after Ms. Whitaker’s departure.
More articles on GI/endoscopy:
The Johns Hopkins Hospital completes 1st MUSE procedures: 5 key facts
$43B by 2019: 6 key trends in the global endoscopy market
5 most read GI articles – April 20 to April 24
